255
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma

, , ORCID Icon, , , , & ORCID Icon show all
Pages 713-725 | Published online: 25 Jun 2021

References

  • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed October 20, 2020.
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
  • McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. Med J Aust. 2018;209(S2):S28–S33. doi:10.5694/mja18.00207
  • Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001;163:924–929. doi:10.1164/ajrccm.163.4.2008014
  • Stubbs MA, Clark VL, McDonald VM. Living well with severe asthma. Breathe (Sheff). 2019;15(2):e40–e49. doi:10.1183/20734735.0165-2019
  • Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147(4):832–838. doi:10.1164/ajrccm/147.4.832
  • Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545–554 e4. doi:10.1016/j.jaip.2017.05.032
  • Chipps BE, Haselkorn T, Paknis B, et al. More than a decade follow-up in patients with severe or difficult-to-treat asthma: the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) II. J Allergy Clin Immunol. 2018;141(5):1590–1597 e9. doi:10.1016/j.jaci.2017.07.014
  • Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
  • Nelsen LM, Cockle SM, Gunsoy NB, et al. Impact of exacerbations on St George’s Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. J Asthma. 2020;57(9):1006–1016. doi:10.1080/02770903.2019.1630640
  • O’Quinn S, Xu X, Hirsch I. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy. 2019;12:21. doi:10.2147/JAA.S190221
  • Panettieri RA Jr., Welte T, Shenoy KV, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;13:115–1126. doi:10.2147/JAA.S240044
  • Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
  • Pavord ID. Mepolizumab, quality of life, and severe eosinophilic asthma. Lancet Respir Med. 2017;5(5):362–363. doi:10.1016/S2213-2600(17)30132-7
  • Nelsen LM, Vernon M, Ortega H, et al. Evaluation of the psychometric properties of the St George’s Respiratory Questionnaire in patients with severe asthma. Respir Med. 2017;128:42–49. doi:10.1016/j.rmed.2017.04.015
  • Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31; discussion 3–7. doi:10.1016/S0954-6111(06)80166-6
  • Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018;52(6):1801444. doi:10.1183/13993003.01444-2018
  • Chen H, Blanc PD, Hayden ML, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health. 2008;11(2):231–239. doi:10.1111/j.1524-4733.2007.00229.x
  • Ambrose CS, Chipps BE, Moore WC, et al. The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results. Pragmat Obs Res. 2020;11:77–90. doi:10.2147/POR.S251120
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi:10.2165/00019053-199304050-00006
  • Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006
  • Livneh H, Wilson LM, Duchesneau A, et al. Psychosocial adaptation to epilepsy: the role of coping strategies. Epilepsy Behav. 2001;2(6):533–544. doi:10.1006/ebeh.2001.0284
  • Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507–1515. doi:10.1016/S0277-9536(99)00045-3
  • Mullerova H, Cockle SM, Gunsoy NB, et al. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study. J Asthma. 2020;1–12.
  • Miller PS, Hill H, Andersson FL. Nocturia work productivity and activity impairment compared with other common chronic diseases. Pharmacoeconomics. 2016;34(12):1277–1297. doi:10.1007/s40273-016-0441-9
  • Sadatsafavi M, Rousseau R, Chen W, et al. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest. 2014;145(4):787–793. doi:10.1378/chest.13-1619
  • US Bureau of Labor Statistics. Median usual weekly earnings of full-time wage and salary workers by sex; 2020. Available from: https://www.bls.gov/charts/usual-weekly-earnings/usual-weekly-earnings-over-time-total-men-women.htm#. Accessed October 31, 2020.
  • Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi:10.1164/rccm.201904-0903SO